
1. hepatology. 2018 jul;68(1):32-47. doi: 10.1002/hep.29814. epub 2018 apr 27.

all-oral direct-acting antiviral therapy hepatitis c virus (hcv) human
immunodeficiency virus/hcv-coinfected subjects real-world practice: madrid
coinfection registry findings.

berenguer j(1), gil-martin á(2), jarrin i(3), moreno a(4), dominguez l(5), montes
m(6), aldámiz-echevarría t(1), téllez mj(7), santos i(8), benitez l(9), sanz
j(10), ryan p(11), gaspar g(12), alvarez b(13), losa je(14), torres-perea r(15), 
barros c(16), martin jvs(17), arponen s(18), de guzmán mt(19), monsalvo r(20),
vegas a(21), garcia-benayas mt(22), serrano r(23), gotuzzo l(24), menendez
ma(25), belda lm(26), malmierca e(27), calvo mj(2), cruz-martos e(2),
gonzález-garcía jj(6).

author information: 
(1)hospital general universitario gregorio marañón/iisgm, madrid, spain.
(2)subdirección general de farmacia productos sanitarios/sermas, madrid, spain.
(3)instituto de salud carlos iii, madrid, spain.
(4)hospital universitario ramón cajal, madrid, spain.
(5)hospital universitario 12 de octubre/i+12, madrid, spain.
(6)hospital la paz/idipaz, madrid, spain.
(7)hospital clínico universitario san carlos, madrid, spain.
(8)hospital universitario de la princesa, madrid, spain.
(9)hospital universitario puerta de hierro, majadahonda, spain.
(10)hospital universitario príncipe de asturias, alcalá de henares, spain.
(11)hospital universitario infanta leonor, madrid, spain.
(12)hospital universitario de getafe, getafe, spain.
(13)fundación jiménez díaz, madrid, spain.
(14)fundación hospital de alcorcón, alcorcón, spain.
(15)hospital universitario severo ochoa, leganés, spain.
(16)hospital universitario de móstoles, móstoles, spain.
(17)hospital universitario de fuenlabrada, fuenlabrada, spain.
(18)hospital de torrejón, torrejón de ardoz, spain.
(19)hospital infanta cristina, parla, spain.
(20)hospital del tajo, aranjuez, madrid, spain.
(21)hospital infanta elena, valdemoro, spain.
(22)hospital universitario del sureste, arganda, spain.
(23)hospital del henares, coslada, spain.
(24)hospital rey juan carlos, móstoles, spain.
(25)hospital gómez ulla, madrid, spain.
(26)hospital del escorial, el escorial, spain.
(27)hospital infanta sofía, san sebastián de los reyes, spain.

we evaluated treatment outcomes prospective registry human
immunodeficiency virus/hepatitis c virus (hcv)-coinfected patients treated with
interferon-free direct-acting antiviral agent-based therapy hospitals the
region madrid november 2014 august 2016. assessed sustained
viral response 12 weeks completion treatment used multivariable
logistic regression identify predictors treatment failure. evaluated
2,369 patients, 59.5% cirrhosis, 33.9% compensated
cirrhosis, 6.6% decompensated cirrhosis. predominant hcv genotypes
were 1a (40.9%), 4 (22.4%), 1b (15.1%), 3 (15.0%). treatment regimens
included sofosbuvir (sof)/ledipasvir (61.9%), sof plus daclatasvir (14.6%),
dasabuvir plus ombitasvir/paritaprevir/ritonavir (13.2%), regimens
(10.3%). ribavirin used 30.6% patients. less 1% patients
discontinued therapy owing adverse events. frequency sustained viral
response intention-to-treat analysis 92.0% (95% confidence interval,
90.9%-93.1%) overall, 93.8% (92.4%-95.0%) cirrhosis, 91.0% (88.8%-92.9%)
for compensated cirrhosis, 80.8% (73.7%-86.6%) decompensated cirrhosis.
the factors associated treatment failure male sex (adjusted odds ratio,
1.75; 95% confidence interval, 1.14-2.69), centers diseases control and
prevention category c (adjusted odds ratio, 1.65; 95% confidence interval,
1.12-2.41), baseline cluster differentiation 4-positive (cd4+) t-cell count 
<200/mm3 (adjusted odds ratio, 2.30; 95% confidence interval, 1.35-3.92), hcv 
rna load ≥800,000 iu/ml (adjusted odds ratio, 1.63; 95% confidence interval,
1.14-2.36), compensated cirrhosis (adjusted odds ratio, 1.35; 95% confidence
interval, 0.96-1.89), decompensated cirrhosis (adjusted odds ratio, 2.92; 95%
confidence interval, 1.76-4.87), use sof plus simeprevir, sof plus
ribavirin, simeprevir plus daclatasvir.conclusion: large real-world
study, direct-acting antiviral agent-based therapy safe highly effective 
in coinfected patients; predictors failure included gender, human
immunodeficiency virus-related immunosuppression, hcv rna load, severity liver
disease, use suboptimal direct-acting antiviral agent-based regimens. 
(hepatology 2018;68:32-47).

© 2018 authors. hepatology published wiley periodicals, inc., behalf of
the american association study liver diseases.

doi: 10.1002/hep.29814 
pmcid: pmc6055848
pmid: 29377274  [indexed medline]

